{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:43:36Z","timestamp":1790635416256,"version":"4.1.0"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000032","name":"Institute of Infection and Immunity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["666100"],"award-info":[{"award-number":["666100"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our <jats:italic>in vitro<\/jats:italic> evidence of antiviral activity of interferon (IFN)-\u00df activity against Ebola virus, we conducted a single arm clinical study in Guinea to evaluate the safety and therapeutic efficacy of IFN \u03b2-1a treatment for EVD. Nine individuals infected with Ebola virus were treated with IFN \u03b2-1a and compared retrospectively with a matched cohort of 21 infected patients receiving standardized supportive care only during the same time period at the same treatment unit. Cognizant of the limitations of having treated only 9 individuals with EVD, the data collected are cautiously considered. When compared to supportive care only, IFN \u03b2-1a treatment seemed to facilitate viral clearance from the blood and appeared associated with earlier resolution of disease symptoms. Survival, calculated from the date of consent for those in the trial and date of admission from those in the control cohort, to the date of death, was 19% for those receiving supportive care only, compared to 67% for those receiving supportive care plus IFN \u03b2-1a. Given the differences in baseline blood viremia between the control cohort and the IFN-treated cohort, an additional 17 controls were included for a subset analysis, from other treatment units in Guinea, matched with the IFN-treated patients based on age and baseline blood viremia. Subset analyses using this expanded control cohort suggests that patients without IFN \u03b2-1a treatment were ~ 1.5\u20131.9 fold more likely to die than those treated. Viewed altogether the results suggest a rationale for further clinical evaluation of IFN \u03b2-1a.<\/jats:p>","DOI":"10.1371\/journal.pone.0169255","type":"journal-article","created":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T04:00:48Z","timestamp":1487995248000},"page":"e0169255","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":53,"title":["Interferon \u03b2-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial"],"prefix":"10.1371","volume":"12","author":[{"given":"Mandy Kader","family":"Konde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren P.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fode Amara","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Saliou","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alioune","family":"Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha Amadou","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doussou","family":"Mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Cone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Kaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amento Ablam","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoul Habib","family":"Beavogui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of European Mobile Laboratory Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Pintilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor N.","family":"Fish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"key":"pone.0169255.ref001","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"H Feldmann","year":"2011","journal-title":"Lancet"},{"key":"pone.0169255.ref002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1411249","article-title":"Clinical presentation of patients with ebola virus disease in Conakry, Guinea","volume":"372","author":"EI Bah","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0169255.ref003","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40121-015-0079-5","article-title":"Ebola virus infection: overview and update on prevention and treatment","volume":"4","author":"MJ Martinez","year":"2015","journal-title":"Infect Dis Ther"},{"key":"pone.0169255.ref004","unstructured":"WHO: apps.who.int\/ebola-situation-reports"},{"key":"pone.0169255.ref005","doi-asserted-by":"crossref","first-page":"e1001908","DOI":"10.1371\/journal.pmed.1001908","article-title":"Use of viremia to evalaute the baseline case fatality ratio of ebola virus disease and inform treatment studies: a retrospective cohort study","volume":"12","author":"O Faye","year":"2015","journal-title":"PLOS Med"},{"key":"pone.0169255.ref006","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.it.2012.01.004","article-title":"The yin and yang of viruses and interferons","volume":"33","author":"BX Wang","year":"2012","journal-title":"Trends Immunol"},{"key":"pone.0169255.ref007","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1128\/JVI.02199-05","volume":"80","author":"WB Cardenas","year":"2006","journal-title":"J Virol"},{"key":"pone.0169255.ref008","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1128\/JVI.02163-14","article-title":"Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation","volume":"88","author":"B Yen","year":"2014","journal-title":"J Virol"},{"key":"pone.0169255.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/vim.2014.0066","article-title":"Immune evasion in ebolavirus infections","volume":"28","author":"J Audet","year":"2015","journal-title":"Viral Immunol"},{"key":"pone.0169255.ref010","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/infdis\/jis921","article-title":"Interferon-\u00df therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever","volume":"208","author":"LM Smith","year":"2013","journal-title":"J Infect Dis"},{"key":"pone.0169255.ref011","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/514310","article-title":"Evaluation of immune globulin and recombinant interferon-\u03b12b for treatment of experimental ebola virus infections","volume":"179","author":"PB Jahrling","year":"1999","journal-title":"J Infect Dis"},{"key":"pone.0169255.ref012","first-page":"1","article-title":"mAbs and Ad-vectored IFN-\u03b1 therapy rescue ebola-infected nonhuman primates when administered after the detection of viremia and symptoms","volume":"5","author":"X Qiu","year":"2013","journal-title":"Science Transl Med"},{"key":"pone.0169255.ref013","first-page":"007","article-title":"Evaluation of different strategies for post-exposure treatment of Ebola virus infection in rodents","volume":"S1","author":"JS Richardson","year":"2011","journal-title":"J Bioterr Biodef"},{"key":"pone.0169255.ref014","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1086\/520611","article-title":"Cytokine and chemokine expression in humans infected with Sudan ebola virus","volume":"196","author":"KL Hutchinson","year":"2007","journal-title":"J Infect Dis"},{"key":"pone.0169255.ref015","first-page":"e0004364","article-title":"A rapid screening assay identifies monotherapy with interferon-\u00df and combination therapies with nucleoside analogs as effective inhibitors of ebola virus","volume":"10","author":"SD McCarthy","year":"2016","journal-title":"PLOS NTD"},{"key":"pone.0169255.ref016","unstructured":"WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line worker. http:\/\/www.who.int\/csr\/resources\/publications\/clinical-management-patients\/en\/"},{"key":"pone.0169255.ref017","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"H Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"pone.0169255.ref018","doi-asserted-by":"crossref","first-page":"1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of- Concept Trial in Guinea","volume":"10","author":"D Sissoko","year":"2016","journal-title":"PLOS Med"},{"key":"pone.0169255.ref019","doi-asserted-by":"crossref","first-page":"e1005221","DOI":"10.1371\/journal.ppat.1005221","article-title":"Ebolavirus evolution: past and present","volume":"11","author":"M-A De la Vega","year":"2015","journal-title":"PLOS Pathogens"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0175930","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T00:00:00Z","timestamp":1491955200000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0169255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:22:05Z","timestamp":1634919725000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0169255"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0169255","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0175930","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]}}}